三生製藥(01530.HK)授出1000萬份購股權 擬回購不超10%股份
格隆匯8月25日丨三生製藥(01530.HK)發佈公吿,於2021年8月25日,合共1000萬份購股權已根據其於2015年5月23日採納並於2016年6月28日修訂的首次公開發售後購股權計劃向TMF(Cayman)Ltd.(作為TheEmpireTrust的受託人)授出。承授人為透過日期為2016年9月26日的償付契據而成立的信託。行使價每股7.43港元,公司股份於授出日期的收市價每股7.43港元。
此外,董事會有意根據購回授權行使其權力,以於適當時間於公開市場購回股份。根據購回授權,公司獲准於聯交所購回最多2.55億股股份,即於股東周年大會當日已發行股份總數的10%。
公司的財務狀況穩健。董事會認為,股份的當前成交價格並未反映其內在價值及實際業務前景,併為公司購回股份的良機。董事會相信建議股份購回及其後註銷購回股份可提高股份價值,藉以提升公司股東的回報。此外,建議股份購回反映本公司對自身價值加以肯定,並對行業的長遠前景充滿信心。董事會相信,建議股份購回符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.